GlobalData on MSN

GSK’s Blenrep gains FDA approval for myeloma treatment

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

FDA clears return of GSK’s once-withdrawn multiple myeloma drug

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Fierce Biotech

Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...
Fierce Pharma

GSK's once-withdrawn Blenrep gets 2nd wind in US with FDA nod to treat certain myeloma patients

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
pharmaphorum

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...
Fierce Biotech

ESMO: GSK says 'stay tuned' for more ADC data after partner Hansoh posts 49% response rate

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...
TipRanks on MSN

GSK Expands Share Buyback Program with Latest Purchase

GSK has announced the purchase of 248,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy initiated on ...

BAE buys former GSK drugs factory

A pharmaceutical factory which ceased production earlier this year has been bought by Britain's biggest defence firm. BAE ...